Compare Cincinnati Financial Corporation (CINF) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Summit Therapeutics Inc — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.58B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Cincinnati Financial Corporation is far larger — about 2.2× Summit Therapeutics Inc's market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CINF | SMMT | |
|---|---|---|
Market Cap | $26.58B | $12.06B |
Sector | Financials | Health |
52-Week High | $192.03 | $26.98 |
52-Week Low | $149.79 | $12.55 |
Enterprise Value | $25.71B | $11.39B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $172.55, down 0.75% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing revenue growth. Strong fundamentals include a low P/E of 8.18, robust ROE of 21.48%, and consistent dividend payments, with a recent H1-26 dividend of $0.94 declared.
Outlook remains cautiously optimistic with a consensus price target of $195, implying potential upside. Key risks include catastrophe losses impacting underwriting results and competitive pressures in commercial lines. The stock offers value based on earnings and dividend history but faces near-term headwinds from recent earnings miss and bearish technicals.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
